GS-9688
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GS-9688, covering 2021-01-06 to 2021-01-06. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment [Phase 2]